Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSMOS: Oral to Subcutaneous Methotrexate in RA
NCT06913907Phase 4Recruiting
- Sponsor
- Keio University
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methotrexate in rheumatoid arthritis (RA), sponsored by Keio University. Primary endpoint: Change in Methotrexate Polyglutamate Concentrations in Erythrocytes at 24 weeks. Started Apr 2025; status: recruiting.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06913907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913907.